Gates Foundation's $23M for HIV in India
The Bill and Melinda Gates Foundation has committed to invest $23.0 million to help deal with HIV/AIDS in India, as part of an additional $58.0 million promised to Avahan, the Foundation's India AIDS Initiative, announced Tadataka Yamada, its Global Health Program president and former head of research at drug major GlaxoSmithKline, speaking in India.
During a three-year plan, the $23.0 million will focus on two main areas: program managements; and technical capacity at both national and state levels, so as to enhance the capacity of the Indian government's HIV prevention activities. The Avahan will use the funding to provide support and training for various staff to improve their skills in project management.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze